Advertisement
Screener

IOVANCE BIOTHERAPEUTICS, INC. (IOVA) Noncash or Part Noncash Acquisition, Intangible Assets Acquired

2.3 / 5 stars · 27/60 Roast Me

IOVANCE BIOTHERAPEUTICS, INC. Noncash or Part Noncash Acquisition, Intangible Assets Acquired

IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported Noncash or Part Noncash Acquisition, Intangible Assets Acquired of $0 for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-06.

Financial Statements › Cash Flow › Operating Activities

us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1 · last filed 2026-02-24

  • IOVANCE BIOTHERAPEUTICS, INC. noncash or part noncash acquisition, intangible assets acquired for the quarter ending 2025-09-30 was $0.00.
  • IOVANCE BIOTHERAPEUTICS, INC. noncash or part noncash acquisition, intangible assets acquired for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
  • IOVANCE BIOTHERAPEUTICS, INC. noncash or part noncash acquisition, intangible assets acquired for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
  • IOVANCE BIOTHERAPEUTICS, INC. noncash or part noncash acquisition, intangible assets acquired for the quarter ending 2024-12-31 was $0.00.
  • IOVANCE BIOTHERAPEUTICS, INC. noncash or part noncash acquisition, intangible assets acquired for fiscal 2024 was $17.50M.
Period endNoncash or Part Noncash Acquisition, Intangible Assets Acquired 3 monthNoncash or Part Noncash Acquisition, Intangible Assets Acquired 6 monthNoncash or Part Noncash Acquisition, Intangible Assets Acquired 9 monthNoncash or Part Noncash Acquisition, Intangible Assets Acquired 12 month
2025-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
$0.00
derived: sum of 2 quarters · filed 2025-11-06
$0.00
10-Q · filed 2025-11-06
$0.00
derived: sum of 4 quarters · filed 2026-02-24
2025-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07
$0.00
10-Q · filed 2025-08-07
$0.00
derived: sum of 3 quarters · filed 2026-02-24
-$6.00M
derived: sum of 4 quarters · filed 2026-02-24
2025-03-31$0.00
10-Q · filed 2025-05-08
$0.00
derived: sum of 2 quarters · filed 2026-02-24
-$6.00M
derived: sum of 3 quarters · filed 2026-02-24
$0.00
derived: sum of 4 quarters · filed 2026-02-24
2024-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24
-$6.00M
derived: sum of 2 quarters · filed 2026-02-24
$0.00
derived: sum of 3 quarters · filed 2026-02-24
$17.50M
10-K · filed 2026-02-24
2024-09-30-$6.00M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
$0.00
derived: sum of 2 quarters · filed 2025-11-06
$17.50M
10-Q · filed 2025-11-06
2024-06-30$6.00M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07
$23.50M
10-Q · filed 2025-08-07
2024-03-31$17.50M
10-Q · filed 2025-05-08
2023-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07
$0.00
derived: sum of 2 quarters · filed 2024-11-07
$0.00
10-Q · filed 2024-11-07
2023-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08
$0.00
10-Q · filed 2024-08-08
2023-03-31$0.00
10-Q · filed 2024-05-09

Similar stocks

Stock NameCountryMarket CapPE Ratio
Adaptive Biotechnologies Corp (ADPT)United States$4.719B-53.43
CRISPR Therapeutics AG (CRSP)$5.390B-11.68
Relay Therapeutics, Inc. (RLAY)United States$3.884B-14.30
Scholar Rock Holding Corp (SRRK)United States$5.920B-16.37
CG Oncology, Inc. (CGON)United States$6.095B-27.95
Tarsus Pharmaceuticals, Inc. (TARS)United States$3.329B-58.60
Denali Therapeutics Inc. (DNLI)United States$3.274B-8.04
Immunovant, Inc. (IMVT)United States$7.028B-14.78
Beam Therapeutics Inc. (BEAM)United States$2.549B-41.51
Greenland Mines Ltd (GRML)United States$2.362B